Showing 15 posts of 345 posts found.


Merck/Pfizer’s Bavencio wins slight reprieve after NICE nod

March 1, 2018
Medical Communications, Sales and Marketing Bavencio, Merck, Pfizer, biotech, drugs, pharma, pharmaceutical

Just two weeks ago, Merck KGaA and Pfizer were hit with a major setback for their PD-L1 immunotherapy, Bavencio, after …


MSD poised to acquire viral immuno-oncology firm Viralytics for $394m

February 21, 2018
Research and Development, Sales and Marketing Cancer, MSD, Merck, Viralytics, acquisition, keytruda, oncology, pharma

MSD, known as Merck in the US, has announced it is to buy Australian viral immuno-oncology firm Viralytics for $394 …


Biogen shares hit by key Alzheimer’s drug concerns

February 15, 2018
Research and Development Alzheimer's, Biogen, MSD, Merck, biotech, drugs, pharma, pharmaceutical

Biogen made investors very nervous after it announced that it was choosing to add an additional 510 patients to its …


MSD’s interim Keytruda combo data spooks Roche and BMS

January 16, 2018
Research and Development MSD, Merck, biotech, drugs, keytruda, pharma, pharmaceutical

When PD-1/L1 treatments first came on the market, there was a race to snaffle as many indications as possible for …


Merck KGaA and Pfizer’s Bavencio fails at Phase 3 in gastric cancer

November 28, 2017
Research and Development Bavencio, Cancer, Merck, Pfizer, pharma

Merck KGaA and Pfizer have been rocked by the news that their jointly-developed anti-PD-L1 antibody failed to meet its primary …


NHS England seals access deals with big pharma for breast cancer and MS

November 9, 2017
Sales and Marketing Cancer, Mavenclad, Merck, NHS, NHS England, NICE, Perjeta, Roche, Simon Stevens, breast cancer, multiple sclerosis

NHS England has entered into a commercial agreement with Merck which aims to provide access to innovative treatments for both …

MSD cuts 1,800 jobs in US operations restructure

October 23, 2017
Manufacturing and Production, Sales and Marketing MSD, Merck, job cuts, pharma

MSD has revealed its intention to cut 1,800 sales positions from its workforce in the US. Across the total number, …


MSD gives up on cholesterol drug, despite positive results

October 12, 2017
Medical Communications, Sales and Marketing MSD, Merck, biotech, cholesterol, drugs, pharma, pharmaceutical

MSD, known as Merck in North America, has revealed that it will not pursue a regulatory filing for its cholesterol …

Merck and Pfizer’s joint skin cancer drug gets EU approval

September 21, 2017
Sales and Marketing Bavencio, Cancer, Merck, Pfizer, merkel cell carcinoma, pharma, pharmaceutical, skin canceer

Merck KGaA and Pfizer have announced that European authorisation of their jointly developed drug Bavencio (avelumab) as a monotherapy in …


Merck KGaA commits to continued partnership with Ugandan Government

September 5, 2017
Manufacturing and Production, Medical Communications Merck, infertility, life sciences, pharma, pharmaceuticals, uganda

Merck KGaA has revealed plans to continue its commitment to a key partnership with the Ugandan Government via its non-profit …

MSD CEO sparks exodus from Trump’s manufacturing council over Charlottesville violence

August 15, 2017
Manufacturing and Production MSD, Merck, Prsident's American Manufacturing Council, charlottesville, pharma, pharmaceuticals

In a shock move, MSD Chairman and Chief Executive Officer Kenneth Frazier (pictured) has announced that he is to resign …


Top Ten most popular articles on this week

August 11, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing FDA, Merck, NICE, Parkinson's, biotech, diabetes, pharma, pharmaceutical, top ten

Another week, another busy week in pharma. The last seven days have seen some remarkable strides in the diabetes space, …

Merck scores expanded NICE recommendation in head, neck and oral cancer

August 8, 2017
Manufacturing and Production, Sales and Marketing Erbitux, Merck, NICE, biotech, cetuximah, drugs, life sciences, pharma, pharmaceuticals

Merck has announced its approval of NICE’s decision to expand its recommendation of Erbitux (cetuximab) to include its use as …

AZ attempts to clear dust of Mystic trial with $8.5 billion MSD deal

July 27, 2017
Medical Communications, Sales and Marketing AstraZeneca, MSD, Merck, biotech, drugs, immunotherapy, mystic, pharma, pharmaceutical

It will be some time before the Mystic catastrophe hoo-ha dies down for AstraZeneca but it made a pre-emptive move …

Latest content